Recent clinical data suggest remarkable activity of ibrutinib, the first-in-class covalent inhibitor of Bruton's tyrosine kinase (BTK), in chronic lymphocytic leukemia (CLL), as well as excellent activity in other B cell malignancies, including in particular mantle cell lymphoma and Waldenstrom macroglobulinemia. This review evaluates the data from ongoing clinical and correlative studies of ibrutinib in B cell malignancies with a particular focus on CLL, and considers these data in the context of other B cell receptor pathway inhibitors.
Recent clinical data suggest remarkable activity of ibrutinib , the first - in - class covalent inhibitor of Bruton 's tyrosine kinase ( BTK ) , in chronic lymphocytic leukemia ( CLL ) , as well as excellent activity in other B cell malignancies , including in particular mantle cell lymphoma and Waldenstrom macroglobulinemia . This review evaluates the data from ongoing clinical and correlative studies of ibrutinib in B cell malignancies with a particular focus on CLL , and considers these data in the context of other B cell receptor pathway inhibitors .
What is the name of Bruton's tyrosine kinase inhibitor that can be used for treatment of chronic lymphocytic leukemia?
What is the name of Bruton 's tyrosine kinase inhibitor that can be used for treatment of chronic lymphocytic leukemia ?
Ibrutinib
Ibrutinib